NCT04843007View on ClinicalTrials.gov

Alvopem® (Pemetrexed) Safety Assessment

CompletedOBSERVATIONAL
Enrollment

199

Participants

Timeline

Start Date

March 15, 2016

Primary Completion Date

January 22, 2020

Study Completion Date

January 22, 2020

Conditions
Non Small Cell Lung CancerMalignant Pleural Mesothelioma
Interventions
DRUG

Pemetrexed

Alvopem® was administered every 3 weeks with a dose of 500 mg/m\^2

All Listed Sponsors
lead

NanoAlvand

INDUSTRY

NCT04843007 - Alvopem® (Pemetrexed) Safety Assessment | Biotech Hunter | Biotech Hunter